Anavex Life Sciences Corp (AVXL)

[falconer66a]

Intermittent Prophylactic Dosings

The laying out of on-off blarcamesine (Anavex 2-73) dosing schedules in the treatment of Alzheimer's disease, in the new Anavex patent application, raises the question of intermittency in prophylactic uses of the drug.

Blarcamesine, by activating the sigma-1 receptor protein, presently successfully treats a number of CNS diseases --- awaiting bureaucratic authentication by the FDA. The question then arises, might the drug actually prevent the onset of Alzheimer's, etc., if given before the disease first appears. Prophylaxis; disease prevention.

Now, if that proves to be the case (I personally believe that will happen), would the drug then be used for that purpose? Now, with the on-off dosing schedules listed in the new patent application, it's possible that blarcamesine will prevent various CNS diseases with varying intermittent dosing schedules. Perhaps it will be discovered that to gain the benefits of the drug, before diseases set in, it would need to be taken, say, just once a week. Take a 50mg tablet of blarcamesine with breakfast each Monday morning, and stay clear of the diseases it prevents. Effective? Let's see. Convenient? Inexpensive? Certainly.